A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy

2012 ◽  
Vol 7 (2) ◽  
pp. 201-209 ◽  
Author(s):  
Xiaojun Huang ◽  
Fengrong Wang ◽  
Yuhong Chen ◽  
Ting Liu ◽  
Jianxiang Wang ◽  
...  
Keyword(s):  
Fungal Infections ◽  
Invasive Fungal Infections ◽  
Oral Suspension ◽  
First Line ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

2011 ◽  
Vol 17 (7) ◽  
pp. 1973-1983 ◽  
Author(s):  
Joong-Won Park ◽  
Richard S. Finn ◽  
Jun Suk Kim ◽  
Mark Karwal ◽  
Ruby K. Li ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase Ii ◽  
Advanced Hepatocellular Carcinoma ◽  
First Line ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
First Line Therapy ◽  
Line Therapy

Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies

2005 ◽  
Vol 75 (3) ◽  
pp. 227-233 ◽  
Author(s):  
Anna Candoni ◽  
Rosalba Mestroni ◽  
Daniela Damiani ◽  
Mario Tiribelli ◽  
Angela Michelutti ◽  
...  
Keyword(s):  
Fungal Infections ◽  
Hematologic Malignancies ◽  
Invasive Fungal Infections ◽  
Immunocompromised Patients ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial

Haematologica ◽  
2022 ◽  
Author(s):  
Carol Moreno ◽  
Richard Greil ◽  
Fatih Demirkan ◽  
Alessandra Tedeschi ◽  
Bertrand Anz ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Final Analysis ◽  
Lymphocytic Leukemia ◽  
Small Lymphocytic Lymphoma ◽  
First Line ◽  
Open Label ◽  
Phase 3 ◽  
First Line Therapy ◽  
Line Therapy ◽  
Open Label Phase

iLLUMINATE is a randomized, open-label phase 3 study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. Eligible patients were aged ≥65 years, or

Sign in / Sign up

Export Citation Format

Share Document